To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
REUTERS/Issei Kato/File Photo Olympus Corp incoming chief executive Stefan Kaufmann speaks during an interview with Reuters at the company’s headquarters in Tokyo, Japan November 14, 2022.
Reuters
10:43 JST, October 28, 2024
TOKYO (Reuters) – Japanese medical equipment maker Olympus Corp said on Monday that Chief Executive Stefan Kaufmann has stepped down after allegations he purchased illegal drugs, sending its shares sharply lower.
“Upon receiving an allegation that Mr. Stefan Kaufmann had purchased illegal drugs … Olympus, in consultation with outside legal counsel, immediately investigated the facts,” the company said in a statement.
“Based on the results of the investigation, the Board of Directors unanimously determined that Mr. Stefan Kaufmann likely engaged in behaviors that were inconsistent with our global code of conduct, our core values, and our corporate culture.”
Following the board decision, Kaufmann was asked to offer his resignation and he complied, the statement said.
Reuters was unable to reach Kaufmann for comment.
Yasuo Takeuchi, a director who has formerly helmed the company, will carry out the duties of the CEO for the time being, Olympus said.
Olympus shares tumbled 5.7% in morning trade, underperforming the Nikkei average which was up 1.6%.
